A Nano-targeted Co-delivery System Based on Gene Regulation and Molecular Blocking Strategy for Synergistic Enhancement of Platinum Chemotherapy Sensitivity in Ovarian Cancer.

[1]  H. Wahab,et al.  tLyp-1: A peptide suitable to target NRP-1 receptor. , 2022, Bioorganic chemistry.

[2]  S. M. Badr-Eldin,et al.  Progress in Polymeric Micelles for Drug Delivery Applications , 2022, Pharmaceutics.

[3]  Mingxiao Cui,et al.  Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. , 2022, European journal of medicinal chemistry.

[4]  Qi Zhao,et al.  Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy. , 2022, Journal of the American Chemical Society.

[5]  Guobin Wang,et al.  Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA. , 2021, Acta biomaterialia.

[6]  N. Chattipakorn,et al.  Platinum-based Chemotherapy and Bevacizumab Instigate the Destruction of Human Ovarian Cancers via Different Signaling Pathways. , 2021, Biochemical pharmacology.

[7]  Nalini Devarajan,et al.  Tumor hypoxia: the major culprit behind cisplatin resistance in cancer patients. , 2021, Critical reviews in oncology/hematology.

[8]  M. Karimov,et al.  The combined disulfide cross-linking and tyrosine-modification of very low molecular weight linear PEI synergistically enhances transfection efficacies and improves biocompatibility. , 2021, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  J. Ji,et al.  Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles , 2021, Nature Communications.

[11]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[12]  S. Jordan,et al.  Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis. , 2020, Gynecologic oncology.

[13]  Liu Cao,et al.  Septin4 promotes cell death in human colon cancer cells by interacting with BAX , 2020, International journal of biological sciences.

[14]  Xun Sun,et al.  Improved melanoma suppression with target-delivered TRAIL and PaclitaxSel by a multifunctional nanocarrier. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[15]  P. Neven,et al.  Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer , 2020 .

[16]  Xiaoxuan Liu,et al.  A stimuli-responsive combination therapy for recovering p53-inactivation associated drug resistance. , 2020, Materials science & engineering. C, Materials for biological applications.

[17]  D. Slade.  PARP and PARG inhibitors in cancer treatment. , 2020, Genes & development.

[18]  T. Stiewe,et al.  How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[19]  Claudia Battistella,et al.  Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells with PHPMA-Zosuquidar Conjugates. , 2017, Biomacromolecules.

[20]  Xin Wu,et al.  Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[21]  S. Kaye.  Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  S. Tangutoori,et al.  PARP inhibitors: A new era of targeted therapy. , 2015, Maturitas.

[23]  Mohammad Ariful Islam,et al.  Major degradable polycations as carriers for DNA and siRNA. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Siling Wang,et al.  Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. , 2013, Biomaterials.

[25]  Xiao-ling Fang,et al.  Mechanism of inhibition of P-glycoprotein mediated efflux by Pluronic P123/F127 block copolymers: relationship between copolymer concentration and inhibitory activity. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[26]  J. López-Novoa,et al.  Subcellular targets of cisplatin cytotoxicity: an integrated view. , 2012, Pharmacology & therapeutics.

[27]  W. Fan,et al.  Degradable polyethylenimine derivate coupled to a bifunctional peptide R13 as a new gene-delivery vector , 2012, International journal of nanomedicine.

[28]  N. Matsumura,et al.  Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition. , 2007, Gynecologic oncology.

[29]  M. Fraser,et al.  Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. , 2006, Gynecologic oncology.

[30]  U. Greber,et al.  Signalling takes control of nucleo‐cytoplasmic trafficking , 2002, EMBO reports.

[31]  S. Pilotti,et al.  p53 in drug resistance in ovarian cancer , 1997, The Lancet.

[32]  S. Kjaer,et al.  P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study. , 2006, Gynecologic oncology.